AnaptysBio, Inc.

ANAB • Biotechnology

$45.43

▼ -3.81 (-7.74%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$1.64B

Crecimiento

4.6%

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Márgenes estables o en mejora · -5.6%Crecimiento positivo de ingresos · 38.4%Flujo de caja libre positivo · 0.71Nivel de deuda manejable · 0.38Liquidez saludable · 9.07

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 25 sept 2026, 12:06 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$45.43

Change-7.74%

Shares Out35.98M

Market Cap$1.64B

Enterprise Value$1.49B

52W Range13.86 - 72.36

Beta0.41

P/E8.40

P/S6.92

P/B155.29

P/FCF90.97

EV/Sales6.28

Price$45.43

Change-7.74%

Shares Out35.98M

Market Cap$1.64B

Enterprise Value$1.49B

52W Range13.86 - 72.36

Beta0.41

P/E8.40

P/S6.92

P/B155.29

P/FCF90.97

EV/Sales6.28

EV/EBITDA17.38

EV/FCF82.61

Earnings Yield11.91%

FCF Yield1.10%

Dividend Yield0.00%

Gross Margin98.97%

Oper. Margin20.42%

Profit Margin-5.64%

Debt/Eq0.38

Current Ratio9.07

Quick Ratio9.07

Revenue 5Y4.59%

Target$79.17

Target Upside74.27%

Target Median$77.00

Target Range70.00 - 95.00

Volume417.82K

Avg Volume578.35K

EPS Surprise-1.52

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

43/100

Fortaleza financiera

Deuda, caja, estabilidad

75/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

46/100

Por qué este puntaje▼

Márgenes estables o en mejora · -5.6%Crecimiento positivo de ingresos · 38.4%Flujo de caja libre positivo · 0.71Nivel de deuda manejable · 0.38Liquidez saludable · 9.07

Analyst view

Analyst sentiment and price target

ANAB

Analyst sentiment

Based on 23 analyst votes · 2026-10-20

87/100

Bullish

Hold

Bearish

Precio objetivo

2026-09-25

Bajo

$70.00

Promedio

$79.17

Mediana

$77.00

Alto

$95.00

Resumen de la compañía

IPO: 1/26/2017

Industria: Biotechnology

P/B i: 155.29

Deuda / Patrimonio i: 0.38

Margen operativo: 20.42%

Margen neto: -5.64%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.38

Ratio corriente: 9.07

Ratio rápido: 9.07

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Orwin John A

Transacción: 09/15/2026

VENTA

Cambio

-1,300

Precio

Not reported

Presentación

09/17/2026

Tipo

VENTA

Orwin John A

Transacción: 09/15/2026

COMPRA

Cambio

+1,300

Precio

Not reported

Presentación

09/17/2026

Tipo

COMPRA

Faga Daniel

Transacción: 03/12/2026

COMPRA

Cambio

+53,334

Precio

Not reported

Presentación

08/07/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Orwin John A	VENTA	-1,300	Not reported	09/15/2026	09/17/2026
Orwin John A	COMPRA	+1,300	Not reported	09/15/2026	09/17/2026
Faga Daniel	COMPRA	+53,334	Not reported	03/12/2026	08/07/2026
Lizzul Paul F.	COMPRA	+16,667	Not reported	03/12/2026	08/07/2026
Orwin John A	VENTA	-6,030	Not reported	06/15/2026	06/17/2026
Orwin John A	COMPRA	+6,030	Not reported	06/15/2026	06/17/2026
RENTON HOLLINGS	VENTA	-6,030	Not reported	06/15/2026	06/17/2026
RENTON HOLLINGS	COMPRA	+6,030	Not reported	06/15/2026	06/17/2026
Schmid John P.	VENTA	-6,030	Not reported	06/15/2026	06/17/2026
Schmid John P.	COMPRA	+6,030	Not reported	06/15/2026	06/17/2026
Murphy Christopher M.	OTRO	0	Not reported	05/11/2026	05/13/2026
Murphy Christopher M.	COMPRA	+25,765	Not reported	05/11/2026	05/13/2026
Hughes Owen	OTRO	0	Not reported	05/11/2026	05/13/2026
Hughes Owen	COMPRA	+11,250	Not reported	05/11/2026	05/13/2026
GRAY SUSANNAH	COMPRA	+11,250	Not reported	04/27/2026	04/29/2026
Faga Daniel	VENTA	-11,000	$31.12	04/20/2026	04/23/2026
Faga Daniel	VENTA	-2,321	$31.12	04/20/2026	04/22/2026
RENTON HOLLINGS	COMPRA	+5,500	$32.17	04/20/2026	04/22/2026
Schmid John P.	COMPRA	+5,500	$32.17	04/20/2026	04/22/2026
Orwin John A	COMPRA	+3,311	$14.29	04/20/2026	04/22/2026

Sobre la compañía

AnaptysBio, Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Fuente - Link

Competidores

BBOT DNTH KOD MNMD NRIX OCS PHAT TSHA URGN XNCR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer.

GlobeNewsWire

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.

Zacks Investment Research

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.

GlobeNewsWire

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

GlobeNewsWire

16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,500 shares of the biotechnology company's stock, valued at approximately $1,114,000. Canada Pension Plan Investment Board owned

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-12	-0.32	-1.84	-1.52
2026-03-03	0.89	1.58	0.69
2025-11-04	-1.06	0.52	1.58
2025-08-07	-1.5	-1.34	0.16
2025-05-05	-1.3	-1.28	0.02
2025-02-27	-1.55	-0.72	0.83
2024-11-05	-1.72	-1.14	0.58
2024-08-05	-1.2	-1.71	-0.51
2024-05-09	-1.54	-1.64	-0.1
2024-03-12	-1.60067	-1.59	0.01067
2023-11-02	-1.72	-1.41	0.31
2023-08-07	-1.6954	-1.5	0.1954